Skip to main content
Spexis AG logo

Spexis AG — Investor Relations & Filings

Ticker · SPEX ISIN · CH0106213793 LEI · 391200S8HJE1I96FIG04 SW Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2023-10-06 Report Publication Anno…
Country CH Switzerland
Listing SW SPEX

About Spexis AG

https://www.polyphor.com/

Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Spexis to host business update conference call on October 9, 2023
Report Publication Announcement Classification · 99% confidence The document is a short press release dated October 6, 2023, announcing that Spexis AG will host a 'business update conference call' on October 9, 2023. It provides dial-in numbers and a webcast link for accessing this future event. This is not the transcript of the call itself, nor is it a full financial report (like 10-K or IR). It is an announcement about an upcoming event where management will discuss business and financial updates. This fits best under the category of a Call Transcript (CT) if it were the transcript, but since it is the *announcement* of the call, and it doesn't fit other specific categories like ER (Earnings Release) or DIV (Dividend Notice), it is most appropriately classified as a general announcement related to investor communications. However, given the options, an announcement about an upcoming conference call, especially one providing details for access, is often grouped with investor relations materials. Since 'Call Transcript' (CT) is defined as the *full text transcript*, and this is the *announcement* of the call, the closest fit among the options that deals with scheduled investor discussions is often the 'Call Transcript' category if the system lumps announcements of calls there, or 'Regulatory Filings' (RNS) as a fallback. Given the content is purely logistical information about an upcoming call, and not a formal regulatory filing like a major shareholding change or director dealing, RNS is a safe fallback. However, if the system interprets 'business update conference call' as the primary subject matter, and given the short length (under 5,000 characters) and the nature of announcing an event, it is often classified as a general announcement. Since there is no specific 'Conference Call Announcement' code, and it is not the transcript itself, I will use the fallback 'RNS' as it is a general announcement. Revisiting the definitions: It is not an Earnings Release (ER) as it doesn't contain results. It is not an Investor Presentation (IP). It is an announcement about a call. If the system expects announcements of calls to be classified as CT, that would be a misclassification based on the definition provided ('Full text transcript'). Therefore, RNS (Regulatory Filings / miscellaneous announcements) is the most appropriate fallback for an announcement of a future event.
2023-10-06 English
Spexis provides business update and announces financial results for the first half of 2023
Earnings Release Classification · 100% confidence The document is explicitly titled as an 'Ad hoc announcement pursuant to Art. 53 LR' and announces 'financial results for the first half of 2023'. It contains key financial figures (Net loss for the period, R&D expenses) for the period ending 30.06.2023, presented in a summary format typical of an earnings release or interim report summary. Since it covers a period shorter than a year ('first half of 2023') and provides comprehensive financial details (Income Statement and Balance Sheet tables), it fits the definition of an Interim/Quarterly Report (IR). Although it is an announcement, the content is substantial enough (13,363 characters) and focuses on presenting the results themselves, rather than just announcing the publication of a separate, larger report (which would suggest RPA/RNS). The presence of the link to the 'half year report 2023' suggests this document acts as the primary release of the interim results. H1 2023
2023-09-29 English
Spexis provides business update and announces financial results for the first half of 2023
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and explicitly states that Spexis AG 'announces financial results for the first half of 2023'. It contains key financial figures (Net loss for the period, cash position) for the period ending 30.06.2023, which is a half-year period. This content aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is an announcement, the document contains the actual summarized financial results and business update, making it more than just a 'Report Publication Announcement' (RPA) which typically just points to the full report. Since it covers a period shorter than a year (half year), 'IR' is the most appropriate classification over '10-K'. H1 2023
2023-09-29 English
Spexis announces the appointment of Goncalo Bernardes, Ph.D., as acting Head of Chemical Biology
Board/Management Information Classification · 98% confidence The document is a press release dated September 28, 2023, announcing the appointment of an individual, Gonçalo Bernardes, Ph.D., as the acting Head of Chemical Biology. This type of announcement concerns changes in senior personnel within the company's leadership structure. Based on the provided definitions, this aligns directly with the 'Board/Management Information' category, which covers 'Announcement of changes in the company's board of directors or senior management.' The document is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a general regulatory filing (RNS), but a specific management update.
2023-09-28 English
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
Board/Management Information Classification · 99% confidence The document is a press release from Spexis AG announcing the appointment of a new acting Head of Chemical Biology, Dr. Gonçalo Bernardes. This type of announcement concerns changes in senior personnel within the company's management structure. Based on the provided definitions, the category 'Board/Management Information' (MANG) is the most appropriate classification for announcements regarding changes in senior management.
2023-09-28 English
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin studies
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc' announcement dated August 15, 2023, detailing a capital commitment of USD $2.5 million structured as debt and convertible debt to fund Phase 3 clinical studies (ColiFin®). The key terms are 'capital commitment,' 'secured, interest-bearing debt,' and 'subordinated debt mandatorily converting into equity.' This directly relates to the company raising funds or changing its capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full 10-K, an earnings release (ER), or a dividend notice (DIV).
2023-08-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.